uniQure (QURE) Stock Forecast, Price & News

uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view top-rated stocks.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, July 25th 2022.
View our earnings forecast for uniQure.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Monday, May, 2nd. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.07. uniQure had a net margin of 61.76% and a trailing twelve-month return on equity of 54.85%.
View uniQure's earnings history.

What price target have analysts set for QURE?

8 brokers have issued twelve-month target prices for uniQure's shares. Their forecasts range from $27.46 to $66.00. On average, they expect uniQure's stock price to reach $48.81 in the next year. This suggests a possible upside of 255.7% from the stock's current price.
View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:

• Mr. Matthew Craig Kapusta, CEO & Exec. Director (Age 50, Pay $965.48k) (LinkedIn Profile)
• Mr. Christian Klemt, CFO, Principal Financial Officer & GM of Amsterdam Site (Age 49, Pay $392.6k) (LinkedIn Profile)
• Dr. Alexander E. Kuta Ph.D., Exec. VP of Quality & Regulatory (Age 62, Pay $652.58k)
• Dr. Ricardo Dolmetsch Ph.D., Pres of R&D (Age 53, Pay $626.15k) (LinkedIn Profile)
• Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
• Mr. Pierre Caloz, Chief Operating Officer
• Mr. David Cerveny, Chief Legal Officer, Gen. Counsel & Sec. (Age 55)
• Dr. Tamara Tugal Ph.D., MBA, Bus. Devel. Director
• Ms. Erin Boyer, Chief People & Culture Office
• Ms. Maria E. Cantor, Chief Corp. Affairs Officer (Age 54)

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Who are some of uniQure's key competitors?

Some companies that are related to uniQure include Harmony Biosciences (HRMY), Insmed (INSM), Arvinas (ARVN), PTC Therapeutics (PTCT), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), EQRx (EQRX), OPKO Health (OPK), Sage Therapeutics (SAGE), Turning Point Therapeutics (TPTX), Global Blood Therapeutics (GBT), Emergent BioSolutions (EBS), Schrödinger (SDGR), Ironwood Pharmaceuticals (IRWD) and Aurinia Pharmaceuticals (AUPH).
View all of QURE's competitors.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.36%), State Street Corp (6.03%), Vanguard Group Inc. (2.59%), JPMorgan Chase & Co. (1.90%), Bank of New York Mellon Corp (1.45%) and Federated Hermes Inc. (1.28%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure.

Which major investors are selling uniQure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Federated Hermes Inc., Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, Henry James International Management Inc., Citigroup Inc., Jane Street Group LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure or view top insider-selling stocks.

Which major investors are buying uniQure stock?

QURE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Assenagon Asset Management S.A., JPMorgan Chase & Co., Acadian Asset Management LLC, BlackRock Inc., Integral Health Asset Management LLC, UBS Group AG, and Robeco Institutional Asset Management B.V..
View insider buying and selling activity for uniQure or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $13.72.

How much money does uniQure make?

uniQure has a market capitalization of $640.01 million and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or $6.89 on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 463 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272.